Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | LIPE | Q05469 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25323532 | 1.00 | ALDH1A1 (0.33) | ALDH1A1LMNAMAPTLIPEMEN1 | |
| SCHEMBL10280081 | 0.83 | EPHX1 (0.36) | ALDH1A1LMNAMAPTLIPEEPHX1 | |
| SCHEMBL9895236 | 0.83 | MAPT (0.31) | MAPTLIPE | |
| SCHEMBL7489016 | 0.82 | KMT2A (0.33) | LMNAMEN1KMT2A | |
| SCHEMBL1914601 | 0.82 | KMT2A (0.33) | LMNAMEN1KMT2A | |
| SCHEMBL7443702 | 0.82 | KMT2A (0.33) | LMNAMEN1KMT2A | |
| SCHEMBL8004785 | 0.78 | NR1H2 (0.42) | ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL15317038 | 0.78 | NR1H2 (0.42) | ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL26676803 | 0.75 | LIPE (0.43) | ALDH1A1LMNAMAPTLIPEMEN1 | |
| SCHEMBL17892797 | 0.75 | HCAR2 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2470525-A1 | PIPERIDINE DERIVATIVES USED AS OREXIN ANTAGONISTS | Glaxo Group Limited (GB) | 2012-07-04 | — | — | EP | disclosed |
| EP-2470523-A1 | 5-METHYL-PIPERIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS FOR THE TREATMENT OF SLEEP DISORDER | Glaxo Group Limited (GB) | 2012-07-04 | — | — | EP | disclosed |
| US-20120149723-A1 | 5-METHYL-PIPERIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS FOR THE TREATMENT OF SLEEP DISORDER | GLAXO GROUP LIMITED (GB) | 2012-06-14 | — | — | US | disclosed |
| US-20120149711-A1 | PIPERIDINE DERIVATIVES USED AS OREXIN ANTAGONISTS | GLAXO GROUP LIMITED | 2012-06-14 | — | — | US | disclosed |
| US-20110053979-A1 | PYRIDINE DERIVATIVES USED TO TREAT OREXIN RELATED DISORDERS | GLAXO GROUP LIMITED (GB) | 2011-03-03 | — | — | US | disclosed |
| WO-2009124956-A1 | PYRIDINE DERIVATIVES USED TO TREAT OREXIN RELATED DISORDERS | GLAXO GROUP LIMITED (GB) | 2009-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149711-A1 | PIPERIDINE DERIVATIVES USED AS OREXIN ANTAGONISTS | HCRTR2, HCRTR1, OXTR | ALDH1A1 2505/4885LMNA 3400/4885MAPT 1240/4885 |
| US-20120149723-A1 | 5-METHYL-PIPERIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS FOR THE TREATMENT OF SLEEP DISORDER | HCRTR2, HCRTR1, HTR5A | ALDH1A1 1963/4885LMNA 3887/4885MAPT 2139/4885 |
| US-20110053979-A1 | PYRIDINE DERIVATIVES USED TO TREAT OREXIN RELATED DISORDERS | HCRTR2, HCRTR1, NPY4R | ALDH1A1 1635/4885LMNA 3195/4885MAPT 534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.